A family history of uterine cancer prompted the patient to seek a hysterectomy.
Modern Medicine Feature Articles
The following board members - both past and current - authors and collaborators will be appearing in Austin at the ACOG Annual Clinical and Scientific Meeting in April. Here is a rundown on where you can find them, the programs they will be participating in, plus links to their recent articles in Contemporary OB/GYN.
Analysis of data from more than 50 million pregnancy-related hospitalizations shows that more needs to be done to identify new mothers at high risk for heart failure (HF) before they leave the hospital. Plus: Incidence of occult cancer during benign gynecology surgery is low but not insignificant. Also: According to a recent study, nearly 5% of non-pregnant women of childbearing age experience major depression, but less than half of those patients use antidepressants.
ERPs may take a year or two to get gong but the benefits to patients and the healthcare system can be significant.
Enhanced recovery pathways (ERP) are rapidly gaining acceptance and use in gynecologic surgery. These handouts from the ERAS Society provide the physician and patient with valuable information for both pre- and post-operative care.
The Food and Drug Administration (FDA) has issued an order restricting sales and distribution of the contraceptive device Essure. Plus: Can a Pap test one day be used to diagnose ovarian, endometrial cancers?
A collection of standards, guidelines, tools and articles for further reading on maternal mortality. ACOG guidelines for emergencies and adverse effects; resources for coping with the death of a patient. Plus, news from Haiti about using mobile technology to save mothers.
A 26-year-old G0 comes to the office complaining of dysuria and painful lesions on her vulva. Can you make the correct diagnosis and treatment plan?
Contemporary OB/GYN will post links to reports on OB hospital closures to help illustrate the impact these closures have on their patients and maternal mortality rates. Be sure to check back often for the very latest links and information.
The U.S. Food and Drug Administration (FDA) has done women a disservice by incompletely examining the evidence for risk and benefits associated with morcellation for women undergoing surgery for suspected fibroids. Of note, within days of the FDA report, the Agency for Healthcare Quality and Research (AHRQ) of the US Department of Health and Human Services published a more rigorous and complete analysis of available data with entirely different results and conclusions. Thirty-six signees recommend that Contemporary OB/GYN’s readers review the AHRQ findings and decide which report serves women best.